Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
N Lamers-Kok, D Panella, AM Georgoudaki… - Journal of Hematology & …, 2022 - Springer
Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct
recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly …
recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly …
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
A Valeri, A García-Ortiz, E Castellano… - Frontiers in …, 2022 - frontiersin.org
Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …
T cell based immunotherapy for cancer: approaches and strategies
T cells are critical in destroying cancer cells by recognizing antigens presented by MHC
molecules on cancer cells or antigen-presenting cells. Identifying and targeting cancer …
molecules on cancer cells or antigen-presenting cells. Identifying and targeting cancer …
Nanomedicines for overcoming cancer drug resistance
T Hu, H Gong, J Xu, Y Huang, F Wu, Z He - Pharmaceutics, 2022 - mdpi.com
Clinically, cancer drug resistance to chemotherapy, targeted therapy or immunotherapy
remains the main impediment towards curative cancer therapy, which leads directly to …
remains the main impediment towards curative cancer therapy, which leads directly to …
Immunogenomics of killer cell immunoglobulin-like receptor (KIR) and HLA class I: coevolution and consequences for human health
NR Pollock, GF Harrison, PJ Norman - The Journal of Allergy and Clinical …, 2022 - Elsevier
Interactions of killer cell immunoglobin-like receptors (KIR) with human leukocyte antigens
(HLA) class I regulate effector functions of key cytotoxic cells of innate and adaptive …
(HLA) class I regulate effector functions of key cytotoxic cells of innate and adaptive …
A new approach to overcoming resistance to immunotherapy: nanotechnology
J Shao, Y Jin, C Jin - Frontiers in Oncology, 2023 - frontiersin.org
Immunotherapy for immune response has ushered in a new era of cancer treatment. In
recent years, new immunotherapeutic agents have been introduced into clinical trials and …
recent years, new immunotherapeutic agents have been introduced into clinical trials and …
Bi-and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
I Abou Dalle, R Dulery, N Moukalled, L Ricard… - Blood Cancer …, 2024 - nature.com
Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing
the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the …
the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the …
Engineered microphysiological systems for testing effectiveness of cell-based cancer immunotherapies
Simple Summary Cell therapy has transformed oncology and drug development, yet better
model systems are needed to recapitulate the tumor immune microenvironment (TIME) …
model systems are needed to recapitulate the tumor immune microenvironment (TIME) …
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors
The translation of natural killer (NK) cells to the treatment of malignant disease has made
significant progress in the last few decades. With a variety of available sources and …
significant progress in the last few decades. With a variety of available sources and …
CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer
M Tarannum, K Dinh, J Vergara, G Birch… - Science …, 2024 - science.org
Epithelial ovarian cancer (EOC) remains one of the most lethal gynecological cancers.
Cytokine-induced memory–like (CIML) natural killer (NK) cells have shown promising results …
Cytokine-induced memory–like (CIML) natural killer (NK) cells have shown promising results …